Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

Table 1 Characteristics of metastatic colorectal cancer patients treated with anti-epidermal growth factor receptor therapy (n = 43) n (%)

Clinico-pathological feature	Frequency
Age (yr), median (range)	64 (26-82)
Gender
Male	26 (60.5)
Female	17 (39.5)
Response
Progressive disease	19 (44.2)
Partial response	13 (30.2)
Stable disease	11 (25.6)
EGFR
No Amplification/gene copy number gain	4 (10.5)
Amplification/gene copy number gain	34 (89.5)
K-RAS
Wild-type	32 (74.4)
Mutation	11 (25.6)
B-RAF
Wild-type	38 (88.4)
Mutation	5 (11.6)
PIK3CA
Wild-type	41 (95.4)
Mutation	2 (4.7)
PTEN
Negative	12 (27.9)
Positive	31 (72.1)
Overall survival time (mo), median (range)	37.3 (3.6-180)
Progression-free survival (mo), median (range)	16.0 (1-171)
Number of tumor buds, median (range)	9.0 (1-44)
Tumor budding
High	11 (25.6)
Low	32 (74.4)

EGFR: Epidermal growth factor receptor.